Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates by Christie P. M. Verkleij, Wassilis S. C. Bruins, Sonja Zweegman, Niels W. C. J. van de Donk

Get full text

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients by Kristine A. Frerichs, Christie P.M. Verkleij, Patricia W.C. Bosman, Sonja Zweegman, Henny Otten, Niels W.C.J. van de Donk

Get full text

Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma by Mashhour Hosny, Christie P. M. Verkleij, Jort van der Schans, Kristine A. Frerichs, Tuna Mutis, Sonja Zweegman, Niels W. C. J. van de Donk

Get full text

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies by Christie P. M. Verkleij, Amy Jhatakia, Marloes E. C. Broekmans, Kristine A. Frerichs, Sonja Zweegman, Tuna Mutis, Natalie A. Bezman, Niels W. C. J. van de Donk

Get full text

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients by Kristine A. Frerichs, Christie P. M. Verkleij, Meletios A. Dimopoulos, Jhon A. Marin Soto, Sonja Zweegman, Mary H. Young, Kathryn J. Newhall, Tuna Mutis, Niels W. C. J. van de Donk

Get full text

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma by Christie P.M. Verkleij, Kristine A. Frerichs, Marloes E.C. Broekmans, Carolien Duetz, Chloe A. O’Neill, Wassilis S.C. Bruins, Paola M. Homan-Weert, Monique C. Minnema, Mark-David Levin, Annemiek Broijl, Gerard M.J. Bos, Marie José Kersten, Saskia K. Klein, Medya M. Shikhagaie, Tineke Casneuf, Yann Abraham, Tina Smets, Greet Vanhoof, Diana Cortes-Selva, Laure van Steenbergen, Elena Ramos, Raluca I. Verona, Maria Krevvata, Pieter Sonneveld, Sonja Zweegman, Tuna Mutis, Niels W.C.J. van de Donk

Get full text